Praxis Precision Medicines expects FDA approval decisions for two drug candidates within six months, with ulixacaltamide on track for a January 2027 decision and relutrigine due by late December 2026, according to the company's Q2 2026 earnings announcement.
The biotech is building a 300-person field force ahead of ulixacaltamide's potential launch and has set peak annual sales targets exceeding $10 billion for the compound. The dual timeline compresses both programs into the final months of 2026 and early 2027.
Ulixacaltamide is a precision medicine candidate developed for patients with specific genetic markers. Praxis has positioned the drug as a cornerstone asset, allocating significant resources to sales infrastructure and manufacturing readiness. The $10 billion peak sales target is substantial for a single indication.
Relutrigine, the other candidate under FDA review, is expected to receive a decision by December 27, 2026, ahead of ulixacaltamide's January 29, 2027 target date. The staggered timeline allows Praxis to manage regulatory interactions and clinical readiness separately, though both programs are central to the company's near-term growth strategy.
The 300-person field force expansion is among the largest pre-approval sales infrastructure builds in recent biotech history for a single-indication launch. Praxis is recruiting specialists, regional managers and customer service staff now to ensure rapid market penetration if approvals arrive on schedule. Field force size often correlates with peak sales achieved; comparable launches in psychiatry have deployed 200 to 400 sales representatives depending on indication prevalence and physician density.
The two FDA decisions within a six-month window create binary outcomes for the company: successful approvals unlock immediate commercialization of two programs simultaneously, while any delay or rejection would require the company to recalibrate timelines and resource allocation. Praxis has no other late-stage programs approaching decision points, making these two submissions the primary catalysts for 2026 and 2027 growth.
The company's ability to execute dual launches and meet the stated $10 billion ulixacaltamide peak sales figure depends on regulatory approval, manufacturing scale-up and physician adoption rates. Praxis will have built commercial infrastructure ahead of actual product revenue if either FDA decision slips past the announced windows, a cash burn dynamic typical of biotech in the approval-to-launch transition.
The document to watch is the FDA Complete Response Letter or Approval Letter for each program, due on or near the announced dates, as either outcome will immediately reset market expectations for Praxis's 2027 revenue and cash runway.
